# SHR-1210 in Patients With Relapsed or Refractory Extranodal NK/T Cell Lymphoma

> **NCT03363555** · PHASE2 · UNKNOWN · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 97 (estimated)

## Conditions studied

- Extranodal NK/T-cell Lymphoma, Nasal Type

## Interventions

- **DRUG:** SHR-1210

## Key facts

- **NCT ID:** NCT03363555
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-05-29
- **Primary completion:** 2019-06-30
- **Final completion:** 2021-06
- **Target enrollment:** 97 (ESTIMATED)
- **Last updated:** 2020-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03363555

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03363555, "SHR-1210 in Patients With Relapsed or Refractory Extranodal NK/T Cell Lymphoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03363555. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*